170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Other Events
Provides Business Update and Reports Second Quarter 2026 Financial Results
Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Annual Report to Security Holders
Q2
FY 2025
Q3
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload